Fact checked by Nick Blackmer A blood test is now available to screen for colorectal cancer.However, a recent study concluded ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...

Then you have our homegrown Cologuard test from Exact Sciences ... In a recent 10-year European study, folks who got ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based genomic profiling platform with widespread use in breast ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

A physician from MUSC in downtown Charleston says November, known as Men’s Health Awareness Month, is a good opportunity to ...

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening ...

The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential.